Product Description
For Treatment of Chronic Hepatitis C (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01740089)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biocad
Company Location: Europe
Company Founding Year: 2001
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hepatitis C, Chronic|Hepatitis A|HIV Infections|Coinfection|Acquired Immunodeficiency Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01889433 |
BCD-016-3 | P3 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2015-12-02 |
2019-03-19 |
Treatments |
|
NCT02103439 |
BCD-016-4 | P3 |
Completed |
Hepatitis A|HIV Infections|Acquired Immunodeficiency Syndrome|Coinfection|Hepatitis C, Chronic |
2015-08-26 |
2019-03-20 |
Treatments |
|
NCT01740089 |
PEG-IFNа-2 | P3 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2012-07-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|